Nanotechnology applications for improved delivery of antiretroviral drugs to the brain

Advanced Drug Delivery Reviews
Ho-Lun WongReina Bendayan

Abstract

Human immunodeficiency virus (HIV) can gain access to the central nervous system during the early course of primary infection. Once in the brain compartment the virus actively replicates to form an independent viral reservoir, resulting in debilitating neurological complications, latent infection and drug resistance. Current antiretroviral drugs (ARVs) often fail to effectively reduce the HIV viral load in the brain. This, in part, is due to the poor transport of many ARVs, in particular protease inhibitors, across the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSBF). Studies have shown that nanocarriers including polymeric nanoparticles, liposomes, solid lipid nanoparticles (SLN) and micelles can increase the local drug concentration gradients, facilitate drug transport into the brain via endocytotic pathways and inhibit the ATP-binding cassette (ABC) transporters expressed at the barrier sites. By delivering ARVs with nanocarriers, significant increase in the drug bioavailability to the brain is expected to be achieved. Recent studies show that the specificity and efficiency of ARVs delivery can be further enhanced by using nanocarriers with specific brain targeting, cell penetrating ligands or ABC-tran...Continue Reading

References

Nov 11, 1976·Biochimica Et Biophysica Acta·R L Juliano, V Ling
Oct 1, 1988·Scientific American·R YarchoanS Broder
Dec 1, 1994·The Journal of Pharmacy and Pharmacology·M FrestaA Russo
Jul 26, 1996·The Journal of Biological Chemistry·D DerossiA Prochiantz
Apr 1, 1997·The Journal of Neuropsychiatry and Clinical Neurosciences·C G LyketsosG Treisman
Jul 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·J MaherA Nath
Feb 7, 1998·The Journal of Clinical Investigation·R B KimG R Wilkinson
Jun 18, 1998·Cell·D C Chan, P S Kim
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·L A DoyleD D Ross
May 13, 1999·Journal of Neurovirology·A P Kerza-Kwiatecki, S Amini
Jul 8, 1999·Proceedings of the National Academy of Sciences of the United States of America·M Kaul, S A Lipton
Aug 24, 1999·Journal of Acquired Immune Deficiency Syndromes : JAIDS·S KravcikD W Cameron
Oct 26, 1999·Trends in Neurosciences·V C Asensio, I L Campbell
Jun 6, 2000·Advanced Drug Delivery Reviews·R CecchelliM P Dehouck
Feb 13, 2001·Neurology·N SacktorUNKNOWN Multicenter AIDS Cohort Study
Sep 1, 2001·Antiviral Research·M R RuffF A Ruscetti
Jan 31, 2002·Annual Review of Medicine·Joel N BlanksonRobert F Siliciano

❮ Previous
Next ❯

Citations

Jul 2, 2011·Cytotechnology·Xin-Jun Cai, Ying-Ying Xu
Aug 27, 2011·Journal of the American Chemical Society·Hilda A NamanjaJean Chmielewski
Dec 17, 2010·AIDS·Judith SchoutenPeter Portegies
Nov 1, 2011·Pharmacological Reviews·C Yan Cheng, Dolores D Mruk
Mar 23, 2011·Journal of Occupational Medicine and Toxicology·Robert A Yokel, Robert C Macphail
May 1, 2013·PloS One·Thanyanan ChaowanachanKim A Woodrow
Oct 12, 2012·International Journal of Nanomedicine·Supriya D MahajanStanley A Schwartz
Oct 20, 2010·International Journal of Nanomedicine·Rama Mallipeddi, Lisa Cencia Rohan
Sep 13, 2011·Journal of Experimental Stroke & Translational Medicine·Shimin LiuH Richard Winn
Apr 18, 2014·International Journal of Nanomedicine·Maria João GomesBruno Sarmento
Aug 28, 2014·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Casey A MaguireXandra O Breakefield
Mar 5, 2013·Current Opinion in HIV and AIDS·Theodore J CoryCourtney V Fletcher
Oct 22, 2011·Cellular and Molecular Life Sciences : CMLS·Miren Karmele AiertzaIraida Loinaz
Jul 6, 2014·Expert Opinion on Drug Delivery·Ajeet KaushikMadhavan Nair
Mar 21, 2013·Expert Opinion on Drug Delivery·Abeer M Al-GhananeemHieu Tran
Jan 7, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ma Jesús SerramíaMa Ángeles Muñoz-Fernández
Nov 17, 2009·Advanced Drug Delivery Reviews·Alejandro Sosnik, Mansoor Amiji
Sep 15, 2015·International Journal of Biological Macromolecules·Barnabas WilsonJ Josephine Leno Jenita
Mar 17, 2016·Nanomedicine·Inmaculada PosadasValentín Ceña
Jul 14, 2011·The Journal of Pharmacy and Pharmacology·Sanju DhawanBhupinder Singh
Jan 8, 2014·Reviews in Medical Virology·Vidya SagarMadhavan Nair
May 20, 2015·Colloids and Surfaces. B, Biointerfaces·Anil VyasSanjay K Jain
Aug 21, 2013·Biomaterials·Mengjiao ZhouXiaohong Zhang
Oct 26, 2013·The Lancet Infectious Diseases·David B Clifford, Beau M Ances
Nov 27, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ari S NowacekHoward E Gendelman
Jun 27, 2015·Frontiers in Cellular Neuroscience·Venkata Subba Rao AtluriMadhavan P N Nair
May 6, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Giovanna GiacaloneElias Fattal
Jun 26, 2013·European Journal of Integrative Medicine·Iris R BellAudrey J Brooks

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Blood Brain Barrier & Cytokines

Some cytokines are able to cross the blood brain barrier through transport systems and enter the cerebrospinal fluid and interstitial fluid spaces. Here is the latest research on cytokines crossing the blood brain barrier and how this can affect tissues within the CNS.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Blood-Brain Barrier Transport in Neurodegeneration

The blood brain barrier is important for regulating the movement of biomolecules in and out of the brain. For example, membrane transporters in the blood brain barrier can be essential for regulating drug movement and dysregulation of these processes may play a role in neurodegeneration. This feed follows the latest research on this topic.